Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

Stangier, Joachim; Haertter, Sebastian; Liesenfeld, Karl‐Heinz; Wienen, Wolfgang; Feuring, Martin; Clemens, Andreas; van Ryn, Joanne

doi:10.1160/th09-11-0758

Public

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

Published in Thrombosis and Haemostasis • Jan 1, 2010

Authors:

Joachim Stangier

Sebastian Haertter

Karl‐Heinz Liesenfeld

Abstract

Dabigatran etexilate is an oral, reversible direct thrombin inhibitor that is approved in the EU and several other countries for the prevention of venous thromboembolism after elective hip and knee replacement, and is in advanced clinical development for other thromboembolic disorders. Dabigatran ha...

Subject

Dabigatran

Medicine

Direct thrombin inhibitor

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!